A citation-based method for searching scientific literature

Marjan Zarif Yeganeh, Sara Sheikholeslami, Golnoush Dehbashi Behbahani, Samaneh Farashi, Mehdi Hedayati. Tumour Biol 2015
Times Cited: 18







List of co-cited articles
123 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.
Mehdi Hedayati, Marjan Zarif Yeganeh, Sara Sheikhol Eslami, Shekoofe Rezghi Barez, Laleh Hoghooghi Rad, Fereidoun Azizi. J Thyroid Res 2011
24
38

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
L M Mulligan, C Eng, C S Healey, D Clayton, J B Kwok, E Gardner, M A Ponder, A Frilling, C E Jackson, H Lehnert. Nat Genet 1994
548
33

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
988
33

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
327
27

RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
Marjan Zarif Yeganeh, Sara Sheikholeslami, Mehdi Hedayati. Asian Pac J Cancer Prev 2015
15
33

Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.
M Hedayati, I Nabipour, N Rezaei-Ghaleh, F Azizi. Med J Malaysia 2006
17
29

Haplotype Frequency of G691S/S904S in the RET Proto-Onco-gene in Patients with Medullary Thyroid Carcinoma.
Sara Sheikholeslami, Marjan Zarif Yeganeh, Laleh Hoghooghi Rad, Hoda Golab Ghadaksaz, Mehdi Hedayati. Iran J Public Health 2014
10
50

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
27

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Nishant Agrawal, Yuchen Jiao, Mark Sausen, Rebecca Leary, Chetan Bettegowda, Nicholas J Roberts, Sheetal Bhan, Allen S Ho, Zubair Khan, Justin Bishop,[...]. J Clin Endocrinol Metab 2013
147
22

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
H Donis-Keller, S Dou, D Chi, K M Carlson, K Toshima, T C Lairmore, J R Howe, J F Moley, P Goodfellow, S A Wells. Hum Mol Genet 1993
22

Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.
Gisella Figlioli, Stefano Landi, Cristina Romei, Rossella Elisei, Federica Gemignani. Mutat Res 2013
51
22

Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Mehdi Hedayati, Marjan Zarif Yeganeh, Sara Sheikholeslami, Farinaz Afsari. Crit Rev Clin Lab Sci 2016
28
22

MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
Caterina Mian, Gianmaria Pennelli, Matteo Fassan, Mariangela Balistreri, Susi Barollo, Elisabetta Cavedon, Francesca Galuppini, Marco Pizzi, Federica Vianello, Maria Rosa Pelizzo,[...]. Thyroid 2012
90
22

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora, Giancarlo Vecchio, Anderson J Ryan, Gabriella Fontanini, Alfredo Fusco, Massimo Santoro. Cancer Res 2002
482
16

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
Gloria Irene Manfredi, Alessandra Dicitore, Germano Gaudenzi, Michele Caraglia, Luca Persani, Giovanni Vitale. Endocrine 2015
77
16


High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Margarida M Moura, Branca M Cavaco, António E Pinto, Valeriano Leite. J Clin Endocrinol Metab 2011
153
16

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
685
16

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
352
16

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
877
16

Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population.
Ehsan Alvandi, Seyed Mohammad Akrami, Mohsen Chiani, Mehdi Hedayati, Babak Noori Nayer, Mohammad Reza Mohajeri Tehrani, Manouchehr Nakhjavani, Mehrdad Pedram. Thyroid 2011
28
16

Multiple endocrine neoplasia type 2A in an Iranian family: clinical and genetic studies.
Ali Asghar Ghazi, Mahmoud Bagheri, Ali Tabibi, Farzaneh Sarvghadi, Hengameh Abdi, Mehdi Hedayati, Marina Pourafkari, Farrokh Tirgari, Run Yu. Arch Iran Med 2014
8
37

Pathogenetic mechanisms in thyroid follicular-cell neoplasia.
Tetsuo Kondo, Shereen Ezzat, Sylvia L Asa. Nat Rev Cancer 2006
650
16

Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity.
J B HAZARD, W A HAWK, G CRILE. J Clin Endocrinol Metab 1959
700
16

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
C Eng, D Clayton, I Schuffenecker, G Lenoir, G Cote, R F Gagel, H K van Amstel, C J Lips, I Nishisho, S I Takai,[...]. JAMA 1996
777
16

RET tyrosine kinase signaling in development and cancer.
Elena Arighi, Maria Grazia Borrello, Hannu Sariola. Cytokine Growth Factor Rev 2005
311
16

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.
Maria A Kouvaraki, Suzanne E Shapiro, Nancy D Perrier, Gilbert J Cote, Robert F Gagel, Ana O Hoff, Steven I Sherman, Jeffrey E Lee, Douglas B Evans. Thyroid 2005
185
16


Update multiple endocrine neoplasia type 2.
Friedhelm Raue, Karin Frank-Raue. Fam Cancer 2010
87
16

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
Karin Frank-Raue, Lisa A Rybicki, Zoran Erlic, Heiko Schweizer, Aurelia Winter, Ioana Milos, Sergio P A Toledo, Rodrigo A Toledo, Marcos R Tavares, Maria Alevizaki,[...]. Hum Mutat 2011
82
16

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.
M M Moura, B M Cavaco, A E Pinto, R Domingues, J R Santos, M O Cid, M J Bugalho, V Leite. Br J Cancer 2009
103
16

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
Cristina Romei, Stefano Mariotti, Laura Fugazzola, Augusto Taccaliti, Furio Pacini, Giuseppe Opocher, Caterina Mian, Maurizio Castellano, Ettore degli Uberti, Isabella Ceccherini,[...]. Eur J Endocrinol 2010
89
16

Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T Kloos, Charis Eng, Douglas B Evans, Gary L Francis, Robert F Gagel, Hossein Gharib, Jeffrey F Moley, Furio Pacini, Matthew D Ringel, Martin Schlumberger,[...]. Thyroid 2009
823
16


Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.
Jena Hudson, Eric Duncavage, Anna Tamburrino, Paolo Salerno, Liqiang Xi, Mark Raffeld, Jeffrey Moley, Rebecca D Chernock. Exp Mol Pathol 2013
88
16

MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.
Deepak Abraham, Nicole Jackson, Justin S Gundara, JingTing Zhao, Anthony J Gill, Leigh Delbridge, Bruce G Robinson, Stan B Sidhu. Clin Cancer Res 2011
116
16

Vandetanib for the treatment of medullary thyroid carcinoma.
Maryann R Cooper, Soo Yun Yi, Wael Alghamdi, Daniel J Shaheen, Michael Steinberg. Ann Pharmacother 2014
15
13

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
S N Holden, S G Eckhardt, R Basser, R de Boer, D Rischin, M Green, M A Rosenthal, C Wheeler, A Barge, H I Hurwitz. Ann Oncol 2005
259
11

Cancer phenomics: RET and PTEN as illustrative models.
Kevin M Zbuk, Charis Eng. Nat Rev Cancer 2007
174
11

An update on molecular biology of thyroid cancers.
Ozgur Omur, Yusuf Baran. Crit Rev Oncol Hematol 2014
65
11



Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies.
Karen Gómez, Jeena Varghese, Camilo Jiménez. J Thyroid Res 2011
13
15


Thyroid carcinoma, version 2.2014.
R Michael Tuttle, Robert I Haddad, Douglas W Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P Hunt,[...]. J Natl Compr Canc Netw 2014
112
11

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
G Bunone, P Vigneri, L Mariani, S Butó, P Collini, S Pilotti, M A Pierotti, I Bongarzone. Am J Pathol 1999
325
11

RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
Jan Willem B de Groot, Thera P Links, John T M Plukker, Cornelis J M Lips, Robert M W Hofstra. Endocr Rev 2006
231
11

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.
Michelle Croyle, Nagako Akeno, Jeffrey A Knauf, Doriano Fabbro, Xu Chen, Jacqueline E Baumgartner, Heidi A Lane, James A Fagin. Cancer Res 2008
74
11

Tumor angiogenesis.
Robert S Kerbel. N Engl J Med 2008
11

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Francesca Carlomagno, Teresa Guida, Suresh Anaganti, Giancarlo Vecchio, Alfredo Fusco, Anderson J Ryan, Marc Billaud, Massimo Santoro. Oncogene 2004
187
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.